Survival
breast cancer
DISEASE, BREAST CANCER
The follow-up period ended April 1, 2022. The total amount of risk time was 335.4 person-years corresponding to a median follow-up time of 4.41 years (IQR 3.98–5.01 years). During the study period, 92% survived (N = 70) and 82% (N = 62) survived disease free. The 10Overall survival (OS) and invasive disease free survival (IDFS) from the date of inclusion (September 2016–July 2018) in patients enrolled in the NeoToc study receiving standard neoadjuvant breast cancer treatment only and in combination with delta-tocotrienol.